Metrics as of 10/14/2026, 11:37 PM (Berlin time), refresh in progress.
Damora Therapeutics Stock
Damora Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Jennifer A. Jarrett
- Employees
- 7
- Market cap
- $1.1 B
- IPO
- 29/10/2020
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia;…
Damora Therapeutics stock: price history
1D
-1.6%
1W
-12.5%
1M
-24.8%
6M
-30.7%
YTD
-19.9%
1Y
+67.8%
2Y
+174.8%
5Y
-78.4%
10Y
–
Next earnings date
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~91% stronger price swings than usual
Damora Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 19/08/2026.
Ask the agents about Damora Therapeutics
Analyst assessment of Damora Therapeutics
PRICE TARGET LOW
US$40.00
CONSENSUS
US$50.00
MEDIAN
US$50.00
PRICE TARGET HIGH
US$60.00
0
STRONG BUY
3
BUY
0
HOLD
0
SELL
0
STRONG SELL
3
TOTAL · Buy
As of: 29/09/2026
Damora Therapeutics stock metrics
P/E
-0.15
P/B
2.18
EV/EBITDA
-2.24
RETURN ON EQUITY
-6.0%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
66.2%
FLOAT SHARES
40,886,817
AVG. DAILY VOLUME (30D)
717,914
Insider transactions (SEC)
Jarrett Jennifer
Winslow Garrett
Winslow Garrett
Attention
Price since yesterday: -1.6%
Search (Google Trends)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Damora Therapeutics stock
What does Damora Therapeutics do?
Damora Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Jennifer A. Jarrett, the company employs around 7 people.
The IPO was on 29/10/2020; the stock trades on NASDAQ under the ticker DMRA.
What do analysts say about Damora Therapeutics stock?
3 analysts rate the stock, the consensus is Buy (as of 29/09/2026).
The average price target is US$50.00, ranging from US$40.00 to US$60.00, with a median of US$50.00.
This is an external assessment, not a statement by Market Jury.
When does Damora Therapeutics report next?
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly 91% stronger than usual.
Does Damora Therapeutics pay a dividend?
No, Damora Therapeutics currently does not pay a dividend.
Which stocks are comparable to Damora Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Damora Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Damora Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.